Merck announces new data from leading lung cancer clinical development program
Merck announced new data from the company’s leading clinical development program in lung cancer. Key data in NSCLC)include new pooled findings from three trials – KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 - evaluating KEYTRUDA in combination with chemotherapy. August 22, 2019